Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Invion ( (AU:IVX) ) has issued an update.
Invion Limited has secured perpetual exclusive global licenses for its Photosoft™ technology, allowing the company to expand its clinical programs and address significant market opportunities in cancer and infectious diseases. This strategic move enhances Invion’s potential for shareholder value and positions it to capitalize on lucrative markets with unmet medical needs. The transaction involves a series of agreements with NGPDT IP Holdings Pty Ltd and RMW Cho Group Limited, subject to shareholder approval and other conditions, and includes the issuance of up to 36.7 million shares upon achieving specific milestones.
More about Invion
Invion Limited is a company operating in the biotechnology industry, focusing on the development and commercialization of innovative medical technologies. Its primary product, Photosoft™, is a platform technology with applications in treating various human and animal diseases, including cancers and infectious diseases. The company aims to expand its market presence globally by leveraging its proprietary technologies.
YTD Price Performance: -71.07%
Average Trading Volume: 68,965
Technical Sentiment Signal: Sell
Current Market Cap: A$6.94M
Find detailed analytics on IVX stock on TipRanks’ Stock Analysis page.